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Background: Prostate cancer (PCa) is the most common cancer in men in Western countries. In-vitro
and in-vivo studies suggest that oxidative stress (OS) and antioxidants play a key role in the pathogenesis
of chronic diseases including PCa, which is promoted by the production of reactive oxygen species and
impaired antioxidant defense mechanisms. This study evaluates the association between OS and men
with PCa.
Methods: A literature search was carried out on Medline, PubMed, and ScienceDirect databases, as well
as manual searches from inception up to August 2015 using the keywords “Oxidative stress” or “Reactive
oxygen species” or “Lipid peroxidation” AND “Prostate cancer.” All studies including data on the mea-
surement of OS biomarkers in PCa were included.
Results: Twenty-three case control studies were retrieved with sample sizes ranging from 15 to 3,613
(6,439 participants in total). Markers of OS were signiﬁcantly higher in patients with PCa compared with
control groups in 21 studies. Two self-controlled case studies comparing OS between PCa cells and non-
PCa cells in tissue biopsies found OS to be statistically higher in PCa cancer cells. Results on markers of
antioxidant capacity (superoxide dismutase, catalase, glutathione, glutathione reductase, glutathione
peroxidase, uric acid, lutein, lycopene, beta carotein, vitamin A, vitamin C, vitamin E, and total antioxi-
dants) were not completely consistent in their association with PCa.
Conclusions: Upregulated OS proﬁles and impairment of antioxidant defense systems may play a role in
men with PCa. To conﬁrm these ﬁndings, robust clinical trials utilizing a personalized approach which
monitors both OS and antioxidant markers during therapy are warranted.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCa) is the most common malignancy and the
second leading cause of cancer-related mortality in men in the
Westernworld including Australia and the USA.1 PCa is a multifocaliversity of Sydney, Northern Sydn
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ciﬁc Prostate Society, Published bneoplasm, which forms solid tumors of glandular origin. The risk of
PCa increases with age but the etiology and pathogenesis are poorly
understood.2 Clinically localized PCa is managed with observation,
surgery, or radiation treatment; the latter may be combined with
androgen-deprivation therapy (ADT). Menwith metastatic disease3ey Cancer Centre, Royal North Shore Hospital, NSW, Australia.
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Prostate Int 4 (2016) 71e8772are managed almost exclusively with ADT and chemotherapy. The
natural history of untreated PCa is still poorly understood, with a
wide variation in outcomes in patients with apparently similar
cancers based on standard staging and pathological grading.4 Being
able to risk stratify individuals with regard to clinical risk is
therefore necessary in order to personalize therapeutic strategies,
with the aim of minimizing harm to those at low risk, and maxi-
mizing the therapeutic armament to those at highest risk. The most
widely used biomarker to detect and monitor PCa is prostate-
speciﬁc antigen. However, strong clinical and preclinical evidence
for the role of elevated cellular reactive oxygen species (ROS) and
impaired protective mechanisms as a driver of PCa susceptibility4,5
points to the potential clinical utility of these markers. The term
oxidative stress has been used to refer to the imbalance between
levels of ROS and the protective “antioxidant” mechanisms,
resulting in an accumulation of molecular damage in DNA, proteins,
and lipids.5
Several clinical studies have demonstrated that increased OS is
related to PCa and that some antioxidants have the potential to
protect men from PCa.6e8 Multiple in-vitro and in-vivo studies
have attempted to elucidate the mechanisms of initiation and
progression of PCa in relation to OS.9 Oxidative free radicals
caused by multiple factors such as modulation of androgens,
inﬂammation, vitamin D, tumor suppressor protein (p53), anti-
oxidants, and age-related OS may initiate PCa.10 More speciﬁcally,
in men with PCa it has been suggested that serum androgens
promote ROS production and accumulation in PCa cells.10
Androgen-associated redox homeostasis is involved in the signal
transduction network of multimeric redox-sensitive transcription
factors, enzymes, and epigenetic modiﬁcations. Androgens have
been shown to promote cancer by increasing reactive oxygen
derivatives in tissue.11 Androgen-induced ROS levels in prostate
epithelial cells play a critical role in PCa development, progres-
sion, and recurrence.12 Further, studies demonstrate that castra-
tion or estrogen therapy can lead to the regression of cancer in
patients with metastatic PCa.13 Hence, it may be proposed that
ADT combined with antioxidant agents may inhibit the progres-
sion of PCa.14
To date, no robust randomized controlled trials have been
conducted to determine the impact of OS on the risk of devel-
oping PCa. A number of studies have attempted to examine the
effect of exogenous antioxidants in preventing cancer recurrence
and reducing the risk of developing cancer. These studies include
lung,15 breast,16,17 colorectal,18 gastrointestinal,19 head and
neck,20 leukemia,21 bladder cancer,22 and PCa,23,24 and ﬁndings
have been inconsistent. Further, there have been reported risks of
antioxidants instead of their protective effects. The major limi-
tation of these studies is the lack of consideration of the redox
imbalance between oxidation and antioxidants, and the double-
edged effect of exogenous antioxidants. Supplementation of
exogenous antioxidants in the long-term without monitoring the
redox balance can result in beneﬁcial as well as harmful effects
depending on the concentration of ROS and the required
amounts to maintain or re-establish redox homeostasis in each
individual patient.25 Studies suggest that high doses of exoge-
nous antioxidants could paradoxically act as a pro-oxidant by
disrupting the redox balance. Thus, the balance between oxida-
tion and antioxidants is a critical issue to consider in an indi-
vidual patient when assessing the anticancer effect of
antioxidants. To our knowledge, there have been no literature
reviews examining the association between OS and men with
PCa. Furthermore, none of the aforementioned studies have
examined the effect of the redox balance in men with PCa. Thus,
we conducted a systemic review to clarify the association be-
tween OS and men with PCa.2. Materials and methods
2.1. Search strategy
A literature search was carried out on Medline, PubMed, and
ScienceDirect databases from inception up to August 2015 using the
keywords “Oxidative stress” or “Reactive oxygen species” or “Free
radical” or “Lipid peroxidation” AND “Prostate cancer.” A manual
search was also conducted from the retrieved articles. Inclusion
criteria were articles that presented data on OS biomarkers, with
the full article published in English. Acceptable study designs were
case control, nested case control, prospective cohort, or random-
ized control trials. We excluded articles based on animal and cell
models.
2.2. Quality assessment
The quality of each article included in this review was assessed
using the NewcastleeOttawa Scale following the Cochrane
Collaboration recommendation.26,27 The NewcastleeOttawa Scale
was developed jointly by the University of Newcastle (Australia)
and the University of Ottawa (Canada) to assess the quality of
nonrandomized studies to be included in systematic reviews.27 It
has been widely used since at least 2004,28 and the results from
several validation studies have been published.29,30 The total score
ranges from 0 to 9, with a higher score indicating greater quality.
2.3. Data extraction
A review template was developed specifying the key informa-
tion about each study (Tables 1 and 2). Two reviewers (B.O. and S.L.)
independently applied the inclusion and quality assessment
criteria. The two reviewers compared results and resolved any
discrepancies in the published articles.
2.4. Statistical analysis for meta-analysis
The meta-analysis was conducted using a random-effects
model, which assumes that the effect size has a distribution
rather than a ﬁxed value, i.e., the effect size varies within the
population. The summary statistic of interest is the standardized
mean difference; speciﬁcally, the difference in mean for PCa pa-
tients compared with healthy controls, divided by the standard
deviation pooled across these groups. For each effect size we
calculated a 95% conﬁdence interval (CI). Restricted maximum
likelihood estimation was used to estimate the model. Analyses
were conducted using the metafor package in R 3.2.1 (R Foundation
for Statistical Computing, Vienna, Austria). The relevant studies
covered a range of oxidation and antioxidants, but these were
dominated by malondialdehyde (MDA), superoxide dismutase
(SOD), and glutathione peroxidase (GSH-Px), so to allow for com-
parisons of sufﬁcient size and homogeneity, and to avoid the
complication of includingmultiple outcomes per study, we chose to
analyze only MDA, SOD, and GSH-Px. The results presented are an
overall effect size and CI, as well as a forest plot. Heterogeneity of
effects for each outcome was reported using I2, which represents
the percentage of variability due to heterogeneity rather than
chance.
3. Results
3.1. Study characteristics
Twenty-three case control studies were identiﬁed (Fig. 1). In 23
studies, the total number of participants was 6,377 of which 3,558
Table 1
The characteristics of the studies involving oxidative stress and antioxidants.
Author, y, country Study population Study design Sample size
Mean age
Control group Sample collection Outcome
measurement &
method
Clinical variables Results & conclusion
Klotz et al33
1988
Germany
PCa and benign BPH Case control study
2 arms
Total N ¼ 26
Case (n ¼ 16)
66 y
Control
BPH (n ¼ 10)
BPH Tissue specimens Nitric oxide:
iNOS
iNOS
immunostaining
Age, clinical
diagnosis
 Positive iNOS immunostaining was detected
in all sections from patients with prostate
carcinoma. The malignant epithelial cells
were highly positive. However, round cells in
benign tissue stained negative for iNOS.
 Prostate carcinoma tissue had high iNOS
expression, whereas benign tissue did not.
 Epithelial iNOS expression can be used as a
speciﬁc immunohistochemical marker for
prostate carcinoma.
Baltaci et al34
2001
Turkey
High-grade
prostatic
intraepithelial
neoplasia
(PIN)
Case control study
4 arms
Total N ¼ 80
BPH (n ¼ 20)
Low-grade PIN:
(n ¼ 20)
High-grade PIN
(n ¼ 20)
Primary prostatic
adenocarcinomas
(n ¼ 20)
Tissue samples Nitric oxide:
iNOS
iNOS
immunostaining
 Positive iNOS immunostaining was detected
in all samples from all patients; iNOS was
detected in both basal epithelial cells and
secretory cells of the glandular epithelium.
 High-grade PIN and prostatic carcinoma
samples had more intense iNOS
immunostaining than low-grade PIN and BPH
samples.
 In all samples, smooth muscle cells showed
weak or moderate iNOS immunoreactivity
and endothelial cells showed moderate
immunostaining.
 Nitric oxide generated by iNOS may be
involved in prostate tumorigenesis and
further studies with immunohistochemical
and molecular biology are needed to
determine the exact role of iNOS in the
pathogenesis of prostatic carcinoma.
Camphausen et al31
2004
Sweden
PCa Case control study
2 arms
Total N ¼ 15
Case: (n ¼ 15)
Control: Historical
data
Historical data Urine sample Oxidative stress:
8-iso-PGF2 and
15-keto-dihydro-
PGF2
Student t test
ND  No increase in either 8-iso-PGF2_ or 15-keto-
dihydro-PGF2_ in the urine of patients with
PCa compared with in historical normal
controls. No increase in either of the eicosa-
noids during RT to the prostate gland.
Iynem et al35
2004
Turkey
Metastatic PCa
patients
Prospective case
control study
2 arms
Total N ¼ 41
Case:
Metastatic PCa
(n ¼ 21)
69 y
Control (n ¼ 20)
64 y
Healthy volunteer
nonsmokers
Blood samples Oxidative stress:
MDA
Antioxidant status:
GSH, GSH-Px, GR,
GST, and Vit E
ND  Plasma MDA levels were signiﬁcantly higher
and plasma vitamin E levels were
signiﬁcantly lower in the patients compared
with control patients (P  0.001 and
P  0.001).
 Erythrocyte GSH level, activities of
erythrocyte GSH-Px and GR enzyme were
signiﬁcantly lower and erythrocyte GST
enzyme activity was signiﬁcantly higher in
the patients compared to control patients. (P
< 0.01, P  0.001, P < 0.05 and P  0.001,
respectively).
 Plasma MDA levels were found to be
signiﬁcantly decreased after antiandrogenic
supplementation (P < 0.05).
 There were no signiﬁcant differences in
erythrocyte GSH,GR, GSH-Px and plasma
vitamin E levels before and after therapy.
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Table 1 (continued )
Author, y, country Study population Study design Sample size
Mean age
Control group Sample collection Outcome
measurement &
method
Clinical variables Results & conclusion
 Erythrocyte GST activity was found to be
signiﬁcantly elevated after therapy when
compared with baseline (P  0.01).
Yilmaz et al36
2004
Turkey
Newly diagnosed
PCa and
Treated benign
prostatic nodular
hyperplasia
(BPNH) patients
Case control study
with
3 arms
Total N ¼ 121
Case
PCa (n ¼ 21)
66 y
BPNH (n ¼ 50)
64 y
Control (n ¼ 50)
66 y
Age, sex, BMI matched
healthy participants
Blood samples Oxidative stress:
MDA
Antioxidant status:
Cu, Zn, Cu-Zn SOD,
and GSH-Px
Data analysis:
The Mann
eWhitney U-test
PSA level,
transrectal
ultrasonography,
and biopsy
Gleason sum.
 MDA levels were higher and the antioxidant
activity and Zn levels lower in the PCa
groups compared to healthy control and
BPNH groups (P  0.001).
 MDA levels were higher in the advanced PCa
group compared to localized PCa group
(P  0.001).
 MDA and SOD were associated with Gleason
score in PCa patients.
 MDA levels can be used in the diagnosis and
follow-up of PCa.
Miyake H37
2004
Japan
PCa limited to
prostate stage
(T1-T4)
Prospective case
control study
2 arms
Total N ¼ 115
Case (n ¼ 82)
Control (n ¼ 33)
Age-matched healthy
participants
Urine samples Oxidative Stress:
DNA damage:
Urinary 8-OHdG
and creatinine
(Cr)
Serum prostate
Speciﬁc antigen
(PSA)
Data analysis:
The Mann
eWhitney U-test
Serum PSA, clinical
stage, metastasis,
biopsy, Gleason
score
 The ratio of urinary 8-OHdG-to-Cr (8-OHdG/
Cr) was signiﬁcantly higher in patients with
PCa compared to controls (P < 0.05).
 Only age was signiﬁcantly associated with 8-
OHdG/Cr in PCa cases among several clinico-
pathological factors including serum PSA,
clinical T stage, metastasis and Gleason score.
 No signiﬁcant differences in urinary 8-OHdG/
Cr in 42 patients before and after radical
prostatectomy.
 Urinary 8-OHdG/Cr in 40 patients was
signiﬁcantly lower (P < 0.05) after hormonal
therapy compared with before hormonal
therapy.
 Changes in PSA after initial treatment were
not related to changes in urinary 8-OHdG/Cr.
 Oxidative stress may be involved in an early
event in PCa development and androgen
suppression without surgical removal of PCa
is capable of decreasing oxidative DNA
damage.
 Androgen ablation therapy combined with
antioxidant agents could be a novel
therapeutic strategy for inhibiting the
progression of PCa.
Srivastava38
2005
India
PCa and benign BPH Case control study
3 arms
Total N ¼ 107
Case (n ¼ 47)
62 y
BPH (n ¼ 55)
60 y
Control (n ¼ 25)
61 y
Healthy men Blood samples Oxidative stress:
MDA
Antioxidant status:
GST from serum,
GSH-Px and GSH
Data analysis:
One-way ANOVA
ND  Signiﬁcantly higher levels of MDA and GSTs
activities were observed in the serum
(P < 0.005) of PCa and BPH cases compared to
controls.
 GSH concentration and GSH-Px activities
were signiﬁcantly lower in PCa compared
with controls (P < 0.05).
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and Linear
regression model
 Oxidanteantioxidant imbalance may be one
of the major factors responsible for the
development of PCa and benign prostate
hyperplasia.
Almushatat et al39
2006
UK
BPH,
localized and
metastatic
PCa
Case control study
4 arms
Total N ¼ 112
Localized PCa
(n ¼ 40)
70 y
Metastatic PCa
(n ¼ 38)
74 y
BPH (n ¼ 20)
67 y
Control (n ¼ 14)
64 y
Healthy subjects Blood samples Oxidative stress:
MDA
Antioxidant status:
Plasma retinol, a-
tocopherol,
lutein, lycopene,
a-carotene and b-
carotene
Inﬂammation
biomarker: C-
reactive protein
(CRP)
Data analysis:
ANOVA (Kruskal
eWallis and
ManneWhitney
U-test
Age, PSA, Gleason
score, cholesterol
 PCa patients had higher concentrations of
MDA (P < 0.05) and lower circulating
concentrations of lutein (P < 0.05), lycopene
(P < 0.001) and b-carotene (P < 0.05).
 Patients withmetastatic PCa, when compared
to patients with localized disease, had a
higher Gleason score (P < 0.01) and more
hormonal treatment, but lower
concentrations of PSA (P < 0.05), a-tocopherol
(P < 0.05), retinol (p < 0.01), lutein (P < 0.05),
and lycopene (P < 0.01).
 PCa PSA correlated with the concentrations of
the lipid peroxidation product, MDA
(rs ¼ 0.353, P < 0.002) in PCa cases
 CRP was not correlated with the vitamin
antioxidants or MDA.
 In contrast, there was a negative correlation
between MDA concentrations and both
lutein (rs ¼ 0.263, P < 0.020) and lycopene
(rs ¼ 0.269, P < 0.017).
 The lower concentrations of carotenoids, in
particular lycopene, reﬂect disease
progression rather than the systemic
inﬂammatory response in patients with PCa.
Aydin et al40
2006
Turkey
Newly diagnosed
PCa patients and
benign prostatic
hyperplasia
(BPH) patients
Case control study
3 arms
Total N ¼ 85
Case
Nonmetastatic PCa
(n ¼ 25)
68 y
BPH (n ¼ 36)
64 y
Control (n ¼ 24)
65 y
Sex-matched healthy
volunteers
Blood samples Oxidative stress:
MDA
Antioxidant status:
SOD, GSH-Px, CAT,
Cu-Zn SOD
Data analysis:
ANOVA tests
followed by
TukeyeKramer's
multiple
comparisons
test a posteriori
ND  Increased lipid peroxidation (TBARS) with a
concomitant decrease in GSH-Px and CuZn-
SOD activities in the PCa patients versus
controls (P < 0.001) and versus BPH patients
(P < 0.05). Zn levels were lower in PCa pa-
tients versus controls (P < 0.01) with no sig-
niﬁcant changes between BPH and the cancer
group.
 No signiﬁcant differences were observed in
the erythrocyte CAT and Cu levels among
any of the studied groups.
Ozmen et al41
2006
Turkey
PCa Case control study
2 arms
Total N ¼ 41
Case (n ¼ 20)
72 y
Control (n ¼ 21)
66 y
Healthy men Blood samples Oxidative stress:
MDA
Antioxidant status:
Vitamin A,C,E and
selenium in
serum
Fe and trace
element (Ni, Zn,
Co, and Cu)
ND  Vitamin A, C, and E levels were signiﬁcantly
lower and MDA levels signiﬁcantly higher
(P < 0.001) in patients with PCa compared
with controls.
 Se and Zn levels were signiﬁcantly lower, and
levels of Ni, Co, and Cu were higher
(P < 0.001) in patients with PCa compared
with controls.
(continued on next page)
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Table 1 (continued )
Author, y, country Study population Study design Sample size
Mean age
Control group Sample collection Outcome
measurement &
method
Clinical variables Results & conclusion
Data analysis:
Student t test
 Fe levels were not signiﬁcantly different in
patients compared with controls.
 The administration of vitamins A, C, and E,
and Se and Zn may be beneﬁcial in the
prevention and treatment of human PCa.
Surapanenet al42
2006
India
PCa Case control study
2 arms
Total N ¼ 60
Case (n ¼ 30)
Control (n ¼ 30)
Healthy men Blood samples Oxidative stress:
MDA
Antioxidant status:
GSH, SOD, and GST
Data analysis:
unpaired t-test
ND  Erythrocyte MDA & SOD levels were
signiﬁcantly higher in patients with
carcinoma of prostate compared with
controls (P < 0.01 and P < 0.001 respectively).
 GSH levels were signiﬁcantly lower in
patients with carcinoma of prostate
compared with controls (P < 0.01).
 No signiﬁcant change was observed in GST
compared with controls.
 Oxidative stress may be involved in PCa as
evidenced by higher MDA levels and lower
GSH levels.
 Increased activity of antioxidant enzyme may
be a compensatory regulation in response to
oxidative stress.
Yossepowitch43
2007
Israel
PCa completed
either radical
prostatectomy or
receiving
androgen
deprivation
therapy
Case control study
4 arms
Total N ¼ 104
Case: (n ¼ 79)
Localized
undergoing
radical
prostatectomy
(N ¼ 42)
63 y
Metastatic disease
receiving
androgen
deprivation
therapy (n ¼ 37)
HSPC (n ¼ 15)
HRPC (n ¼ 22)
63 y
Control (n ¼ 25)
72 y
Age matched healthy
men
12-h fasting blood
sample
Oxidative stress:
MDA
Antioxidant status:
Uric acid, vitamin E
(a-tocopherol),
copper induced
peroxidation
(CucCL2), nd
Vmax (OD246)
OD max.
Data analysis:
ANOVA on log
transformed data.
Univariate binary
logistic
regression
analyses
Ordinal logistic
regression model
PSA, biopsy,
Gleason score,
age, smoking
history, vitamin
supplements,
and lipid proﬁles
 Compared to control subjects, patients with
localized PCa had no difference in oxidative
stress indexes, whereas those withmetastatic
disease had a shorter lag preceding oxidation
and increased MDA (P < 0.05), each reﬂecting
a state of high oxidative stress.
 In patients with PCa, the probability of
disease progression from localized to
advanced state increased with a shorter lag
preceding oxidation (P < 0.001), increased
MDA (P < 0.03) and decreased uric acid
(P < 0.04).
 Patients with advanced PCa had higher
circulating markers of oxidative stress
compared with controls, as determined by
increased susceptibility of serum lipids to
peroxidation. This association was not
detected in patients with localized cancer and
is not attributable to altered levels of a-
tocopherol.
PCa and BPH Case control study
3 arms
Total N ¼ 30
Case (n ¼ 15)
Healthy males of
similar age
Blood sample Oxidative stress:
MDA
 Plasma MDA levels were signiﬁcantly higher
in patients with both BPH and carcinoma of
Prostate
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Kotrikadze et al44
2008
Georgea
BPH (n ¼ 15)
Control (n ¼ 15)
Antioxidant status:
SOD, CAT,
Ceruloplasmin
(Cp), GSH, GSH-
Px, and
glutathione-
reductase (GR)
Data analysis:
Means of standard
variation
statistics
MINITAB (basic
statistic),
prostate compared to controls (P < 0.001 and
P < 0.001 respectively).
 SOD activity in blood erythrocytes showed
that increase in SOD activity was sharply
manifested in BPH (~1.3 times, P < 0.001),
compared with the control group, while in
PCa, activity of the enzyme decreases versus
control group (~1.6 times, P < 0.0001).
 CAT activity remained unaltered in BPH and
was slightly declined in PCa (0.01).
 Cp was increased in both kind of tumors,
especially in PCa (0.0001), as well as GSH
(0.0001) and GR (0.0001).
 GSH-Px was sharply increased in BPH and
reduced in PCa (0.0001).
 The development of BPH reﬂects relatively
weakly on blood system as activity and
content of antioxidant enzymes do not reveal
marked changes. in contrast to PCa, which
show the reduced functional state of blood
antioxidant enzyme system.
Akinloye
et al45
2009
Nigeria
PCa Case control study
4 arms
Total N ¼ 170
Case (n ¼ 120)
Low-grade
PSA (5e10 ng/mL)
(n ¼ 33),
Medium-grade PSA
(11e20 ng/mL)
(n ¼ 45)
High-grade PSA
(> 20 ng/mL)
(n ¼ 42)
Control (n ¼ 20)
Healthy volunteers
PSA concentration
< 3.0 ng/mL
Blood samples Oxidative stress:
Microsomal
membrane
Antioxidant status:
SOD, CAT, reduced
GSH, Uric acid
and Vitamin C
and E.
Data was analysis:
One-way ANOVA
followed by the
post-hoc Duncan
multiple range
test for analysis of
biochemical data
PSA,
ALT,
AST,
Total bilirubin
 Serum LPO, total bilirubin and alkaline
phosphatase (ALP) were signiﬁcantly
elevated (P < 0.05) in patients with PSA
>11 ng/mL. More speciﬁcally, total bilirubin,
ALP and LPO levels were elevated by 75%, 66%
and 107% in subjects with PSA at 11e20 ng/
mL, and by 167%, 105%, 98% in patients with
PSA 20 ng/mL, respectively.
 SOD and CAT activities were lower (P < 0.05)
in all cancer patients.
 Subjects with a PSA level of 11e20 ng/mL and
PSA >20 ng/mL had signiﬁcantly lower uric
acid and GSH levels (P < 0.05).
 A signiﬁcant reduction (P < 0.05) in plasma
vitamin C and E levels was observed in
these patients. The levels of vitamins C and E
decreased by 27% and 77% in subjects with
PSA >20 ng/mL, and by 25% and 47% in
subjects with a PSA level of 11e20 ng/mL,
respectively.
 Depletion of antioxidants was found in PCa
patients, and an inverse relationship
between antioxidants and PSA values.
Arsova-Saraﬁnovsk
et al46
PCa and BPH Case control study
3 arms
Total N ¼ 312
Cases
Healthy volunteers Blood sample Oxidative stress:
MDA and 8-OHdG
 A similar pattern of alteration in the
oxidative/ nitrosative stress-related
(continued on next page)
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Table 1 (continued )
Author, y, country Study population Study design Sample size
Mean age
Control group Sample collection Outcome
measurement &
method
Clinical variables Results & conclusion
2009
Turkey
Case (n ¼ 107)
BPH (n ¼ 167)
Control (n ¼ 38)
NO2/NO3 and
cGMP
Antioxidant status:
CuZn-SOD, GSH-Px,
and CAT
Data analysis:
ANOVA and Tukey
eKramer
multiple
comparisons test
a posteriori or
KruskaleWallis
nonparametric
test,
Dunn's multiple
comparisons test
Smoking, ily
history cancer,
Gleason s e and
PSA
parameters was found in both, Macedonian
and Turkish studied samples: higher MDA
concentrations in PCa patients versus con-
trols and BPH Groups (P < 0.001) and lower
GSH-Px (P < 0.001) and CuZn-SOD (P < 0.01)
activities in PCa patients versus controls and
BPH groups.
 CAT activity (P < 0.01) was decreased in the
PCa patients versus controls in the Turkish
studied sample.
 PCa patients had increased plasma NO2/
NO3 (P < 0.01) and cGMP levels (P < 0.01)
versus controls and BPH groups in both
studied samples.
 An imbalance in the oxidative stress and
antioxidant status and an altered nitrosative
status were present in PCa patients.
Hoque et al32
2010
USA
PCa Nested case-control
design
2 arms
Total n ¼ 3,613
Case
(n ¼ 1,808)
64 years
Control (n ¼ 1,805)
64 y
Biopsy negative Biopsy and blood
samples
Oxidative stress:
Carbonyl
Data analysis
c2 test for
categorical
variables and t
test for
continuous
variables
and multiple
logistic
regression
analysis
Age, race
educati ,
physica ctivity,
smokin
fruit intak
vegetab intake,
and fam
history PCa,
and BM
 No signiﬁcant associations between PCa risk
nor its aggressiveness and serum levels of
oxidized protein as measured by protein
carbonyls.
Battisit et al47
2011
Brazil
PCa Case control study
3 arms
Total N ¼ 110
Case (n ¼ 55)
Metastatic (n ¼ 23)
Non-metastatic
(n ¼ 32)
Control (n ¼ 55)
Age matched-healthy
men
Blood sample Oxidative stress:
MDA and
carbonylation
Antioxidant status:
CAT,SOD, Vitamin C
and vitamin E
Data analysis:
One-way ANOVA
followed by the
Duncan's
multiple
test.
Metastasi
standar
treatme ,
Gleason
score, fam
history oking
and alc l
intake
 TBARS levels and serum protein
carbonylation were higher (P < 0.005) in
PCa patients than in controls.
 CAT activity was decreased (P < 0.005) and
SOD (P < 0.005) activity was higher in PCa
patients when compared with controls.
Nonprotein thiol levels were increased,
however, serum vitamin C and vitamin E
content were reduced (P < 0.05) in PCa
patients when compared with controls.
 Different parameters analyzed in PCa patients
based on metastasis, treatment and Gleason
score showed changes in oxidative stress
biomarkers and antioxidant defenses. This
may indicate an imbalance in the oxidant/
antioxidant status, supporting the idea that
oxidative stress plays a role in PCa, moreover,
the oxidative proﬁle appear to bemodiﬁed by
bone metastasis, treatment and Gleason
score.
Patients with high
grade prostatic
Case control study
3 arms
Total N ¼ 500
HGPIN (n ¼ 140)
Conﬁrmed biopsy
negative
Urine and biopsy Oxidative stress:
F2IP
BMI race, alth
history mily
 Adjusted geometric mean F2-isoprostane
levels were higher in patients with PCa
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Barocas et al48
2011
USA
intraepithelial
neoplasia (HGPIN)
and PCa
66 y
PCa (n ¼ 200)
68 y
Control (n ¼ 160)
67 y
Data analysis:
Multivariable linear
and logistic
regression was
used
history and other
risk factors
(smoke), b sy,
DRE result
current us f
NSAIDs and tins,
and transr al
ultrasound
prostate v me.
(1.82, 95% CI 1.66e2.00) or high grade pros-
tatic intraepithelial neoplasia (1.82, 95% CI
1.68e1.96) than in controls (1.63, 95% CI 1.49
e1.78, P < 0.001), but were similar across
Gleason scores (P < 0.511).
 The adjusted odds of high grade prostatic
intraepithelial neoplasia and PCa increased
with increasing F2-isoprostane quartile (p-
trend ¼ 0.015 and 0.047, respectively) and
the highest F2-isoprostane quartile was
associated with signiﬁcantly increased odds
of PCa (OR 2.44, 95% CI 1.17e5.09, P ¼ 0.017).
 Urinary F2-isoprostane provides a biomarker
for the role for oxidative stress in prostate
carcinogenesis. F2-isoprostanes may also
serve to estimate the efﬁcacy of interventions
targeting oxidative stress mechanisms in PCa
prevention or treatment.
Wozniak et al49
2012
Poland
PCa limited to
prostate gland
(T1ABCN0M0,
T2ABCN0M0Gx,
and
T1ABCN0M0Gx)
Prospective case
control study
2 arms
Total N ¼ 90
Case (n ¼ 60)
67 y
Control
(n ¼ 30)
62 y
Healthy men. Blood sample Oxidative stress:
TBARS
Antioxidant status:
GSH-Px, CAT, and
SOD
Data analysis:
ANOVA
Age, PSA, Gl on
score, TNM
hemoglob
 Erythrocyte GSH-Px in the patients was lower
than in healthy subjects by 34% (P < 0.001),
50% (P < 0.001), 30% (P < 0.05), and 61%
(P < 0.001), respectively, at all periods.
 No signiﬁcant differences were found by
comparing SOD and CAT in PCa patients
with that of controls.
 After 2 y of treatment, the activity of studied
enzymes demonstrated a decreasing
tendency versus before therapy.
 Blood plasma TBARS concentration was
higher than in controls at all periods, while
erythrocyte TBARS decreased after 2 y
compared with control levels.
 An imbalance of oxidant-antioxidant pro-
cesses occurs in the course of PCa.
 The therapy did not alter the levels of
oxidative stress markers, which may prove
its applicability. Two y is too short a period to
restore the oxidanteantioxidant balance.
PCa Case control study
2 arms
Total N ¼ 537
Case (n ¼ 304)
Healthy individuals Blood and urine
samples.
Oxidative stress:
8-isoPGF2a
Age, PSA, Gl on
score, TNM
(continued on next page)
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Table 1 (continued )
Author, y, country Study population Study design Sample size
Mean age
Control group Sample collection Outcome
measurement &
method
Clinical variables Results & conclusion
Brys et al50
2013
Poland
61 y
Control (n ¼ 233)
65 y
Antioxidant status:
Uric acid and
glucose
Data analysis:
Q-Dixon test, Mann
eWhitney and
Cox regression
analysis
hemoglobin,
Prostate volume
 A statistically increased level of isoprostanes
was present in urine of patients with PCa
compared with control group (P < 0.001).
 The concentration of tested antioxidants (uric
acid and glucose) in blood from patients with
PCa was also higher than in healthy
volunteers (P < 0.001).
 The correlation between increased amount of
UA and lipid peroxidation exists in PCa
patients (in all tested groups) (P < 0.001).
 Correlation between PCa risk and urinary
isoprostanes level was analyzed, and a
positive association was found (relative risk
for highest vs. lowest quartile of urinary
isoprostanes ¼ 1.6; 95% conﬁdence interval
1.2e2.4; p for trend ¼ 0.03).
 Reactive oxygen species induce peroxidation
of unsaturated fatty acid in patients with
PCa, and the level of isoprostanes may be
used as a noninvasive marker for
determination of oxidative stress.
Pande et al51
2013
India
Newly diagnosed
PCa patients
Stage (1-4)
Metastatic (n ¼ 16),
non-metastatic
(n ¼ 24)
Case control study
2 arms
Total N ¼ 80
Case (n ¼ 40)
64 y
Control (n ¼ 40)
68 y
Age-matched healthy
individuals
Venous
blood collection, and
the serum was used
for various
biochemical
and hematologic
investigations
Oxidative stress:
8-OHdG,
carbonyls and
MDA
Antioxidant status:
Total antioxidant
status
Angiogenesis:
VEGF levels
Data analysis:
Student t test,
One-way ANOVA,
Pearson's
correlation
coefﬁcient
PSA level at
diagnosis,
transrectal
ultrasound, and
biopsy Gleason
score
 Serum VEGF, cell proliferation, and oxidative
stress levels were signiﬁcantly higher in
patients with prostate carcinoma compared
with controls
 Levels of 8-OHdG, protein carbonyls, and
MDAwere found to be signiﬁcantly increased
with the progression of disease as depicted by
increased level in advanced PSA, stage,
spread, and Gleason score (P < 0.0001).
 Serum VEGF level and cell proliferation index
were signiﬁcantly associated with PSA, stage,
spread and Gleason score.
 VEGF and cell proliferation index correlated
with increase in levels of oxidative stress
markers.
 All indexes of oxidative stress, angiogenesis,
and cell proliferation share a signiﬁcant
negative correlation with total antioxidant
status.
Kosova
et al52
2014
Turkey
PCa and BPH Prospective case
control study
2 arms
Total N ¼ 40
Case (n ¼ 20)
Control (n ¼ 20)
Age matched BPH Blood sample Oxidative stress:
8-OHdG and
MDA
Caspase-3
Data analysis
ManneWhitney U
test,
Wilcoxon test
Age, sex, weight,
and height
 In PCa patients, MDA and DNA damage levels
were signiﬁcantly higher but caspase-3 levels
were signiﬁcantly lower compared to levels
in benign prostate hyperplasia (P < 0.05).
 Altered pro-oxidant, DNA damage levels may
lead to an increase in oxidative damage and
may consequently play an important role in
prostate carcinogenesis.
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Oh et al / Review of case control studies 81were PCa cases. Seven studies were undertaken in Turkey; three
studies each in India and USA; two studies in Poland; one study
each in Brazil, Georgia, Germany, Japan, Nigeria, Sweden, and the
UK. All study participants were recruited from urology clinics.
Sample sizes ranged from 15 to 3,163.31,32 The mean age of par-
ticipants ranged from 60 years to 74 years. Twenty-three studies
were conducted using a case control study design, 19 were case
control studies, two were prospective, one was nested, and one
was a subset of the Nashville Men's Health study.
Comparative and control groups varied. Two self-controlled
case studies compared oxidation status with the biopsy speci-
mens of PCa cells and non-PCa cells33,34. Twenty-one case control
studies compared oxidation status between patients with PCa and
healthy volunteers. Studies included two arms (n ¼ 11), three arms
(n ¼ 7), or four arms (n ¼ 3). One study used historical data as the
control group, two studies used men with benign prostate hy-
perplasia as the comparator, two studies used a negative biopsy,
and 18 studies used age-matched healthy men as the control
group.
3.2. Oxidative stress and antioxidant status in PCa
Of 23 studies, 21 studies reported at least one of the markers of
OS to be signiﬁcantly higher in patients compared with controls
while two studies reported no signiﬁcant difference. OS was
analyzed on biopsy (n ¼ 2), urine (n ¼ 2), blood (n ¼ 16), and both
urine and blood (n ¼ 3) samples of participants (Tables 1 and 2).
Fifteen studies measured both OS and antioxidant values whilst
eight studies measured OS only. OS value was measured based on
lipid peroxidation (n ¼ 19), protein oxidation (n ¼ 9), or both lipid
and protein peroxidation (n ¼ 5). Eight OS biomarkers were iden-
tiﬁed among 23 studies. Most studies (n¼ 14)measuredMDAwhile
nine studies used different biomarkers including 8-hydroxy-2'
-deoxyguanosine (8-OHdg; n ¼ 4), isoprostanes (n ¼ 4), inducible
nitric oxide synthase (n ¼ 3), carbonylation (n ¼ 2), glycation
(n ¼ 2), microsomal membrane (n ¼ 1), and cyclic guanosine
monophosphate (n ¼ 1).
Markers of antioxidant capacity assessed in the studies (Table 2)
can be categorized as endogenous [catalase (CAT; n ¼ 6); gluta-
thione (GSH; n ¼ 6); glutathione reductase (GR; n ¼ 2); GSH-Px;
n ¼ 7; glutathione S-transferase (GST; n ¼ 3); SOD; n ¼ 8; uric
acid (n ¼ 3); bilirubin (n ¼ 1)]; and exogenous [i.e., markers
reﬂecting dietary intake such as (lutein (n¼ 1); lycopene (n¼ 1); b-
carotein (n ¼ 1); vitamin A (n ¼ 1); vitamin C (n ¼ 3); vitamin E
(n ¼ 4); and total antioxidants (n ¼ 1)]. Twelve studies measured
antioxidant values based on more than two indicators. Three
studies measured antioxidant values based on only one indicator.
Seven studies reported GSH-Px values to be low in patients with
PCa. The values of six other antioxidant indicators (CAT, GSH, GR,
SOD, uric acid, and vitamin E) were more variable, but tended to be
lower in patients comparedwith the control group. Conversely, two
antioxidant indicator values (GST and bilirubin) were higher in
patients.
3.3. Result of meta-analysis
Studies that reported data of sample size, mean value of OS,
mean value of antioxidant, and standard deviationwere included in
the meta-analysis (Figs. 2e4). In studies included in this review,
MDA, SOD, and GSX-Px were themost commonly used indicator for
OS and antioxidants, respectively.
For the comparison of MDA (n ¼ 9), the mean effect size was
2.47 [95% CI (1.42, 3.52)] indicating that MDA levels were signiﬁ-
cantly higher for PCa patients than controls. Heterogeneity for this
outcome was high (I2 ¼ 96%). For the comparison of SOD (n ¼ 13),
Table 2
Oxidative stress and antioxidant proﬁles in prostate cancer patients.
Oxidative biomarkers Antioxidant indicators
Lipid peroxidation Protein peroxidation Endogenous antioxidant Exogenous antioxidant
MDA Microsomal
membrane
Isoprostanes NO2
/NO3
/iNOS/
cGMP
DNA damage
8-OHdg
Carbonylation Glycation
(CML)
CAT GSH GR GSH-Px GST SOD Bilirubin Uric
acid
Lutein, Lycopen,
b-carotein
Vit
A
Vit
C
Vit
E
Total
antioxidant
(TAS)
Klotz et al
1988
þ
Baltaci et al 2001 þ
Camphausen et al 2004 NS
Iynem et al 2004 þ    þ 
Yilmaz et al
2004
þ  
Miyake H
2004
þ
Srivastava et al 2005 þ   þ
Almushatat et al 2006 þ 
Aydin A et al 2006 þ NS  
Ozmen et al 2006 þ   
Surapaneni et al 2006 þ  NS þ
Yossepowitch et al 2007 þ  þ
Kotrikadzet al 2008 þ  þ þ  
Akinloye et al 2009 þ    þ   
Arsova-Saraﬁnovsk et al 2009 þ þ NS   
Hoque et al 2010 NS
Battisit et al 2011 þ þ  þ þ  
Barocas DA et al 2011 þ
Wozniak et al 2012 þ NS  NS
Brys et al
2013
þ þ
Pande et al 2013 þ þ þ 
Kosova
et al 2014
þ þ
Yang et al 2015 NS þ
þ, signiﬁcant increase in prostate cancer; , signiﬁcant decrease in prostate cancer; CAT, catalase; cGMP, cyclic guanosine monophosphate; CML, carboxymethyl-lysine; GR, glutathione reductase; GSH, glutathione; GSH-Px,
glutathione peroxidase; GST, glutathione S-transferase; iNOS, inducible nitric oxide synthase; MDA, malondialdehyde; NS, not signiﬁcant; SOD, superoxide dismutase; Vit, vitamin; 8-isoPGF2, 4-HNE, 4-hydroxy-2-nonenal.
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Fig. 1. Preferred reporting items for systematic reviews and meta-analyses.
Oh et al / Review of case control studies 83the mean effect size was0.62 [95%, CI (1.73, 0.50)], indicating no
differences between PCa patients and controls. Heterogeneity for
this outcome was high (I2 ¼ 96%). For GSX-Px (n ¼ 8), the mean
effect size was 1.01 [95%, CI (1.22, e0.80)], indicating GSX-Px
levels were lower for PCa patients than controls. Heterogeneity
for this outcome, as measured by I2, was 0%.
3.4. Study quality
The overall quality of the studies included in this review,
assessed using the NewcastleeOttawa Scale, was moderate with
an average score of 6.83 (standard deviation¼ 1.19, range, 4e8) on
a nine-point scale. The main areas where quality was lacking were
comparability of cases and controls on the basis of the design and
analysis. Nonreporting of the nonresponse rates was a major
factor for low scores in the provision of well-deﬁned outcome
measures.
4. Discussion
Over the last decades, epidemiological, experimental, and clin-
ical studies have demonstrated that markers of OS are associated
with the development and progression of cancer.9 The present
study seeks to evaluate the association between PCa and OS andantioxidants. Overall, results of our review conﬁrm that markers of
OS are increased in PCa patients compared with healthy controls,
with the strongest andmost consistent circulating biomarker being
MDA. To our knowledge, this is the ﬁrst systemic review conducted
to examine the association between OS and antioxidants in men
with PCa.
The present study found that most OS biomarkers were signif-
icantly higher in patients with PCa than the control group. Of 23
studies, 21 studies reported at least onemarker of OS to be higher in
men with PCa, whereas two studies did not detect any signiﬁcant
differences between the two groups. These results are consistent
with recent studies examining the correlation of OS and the risk of
cancer in various tumor groups which reported signiﬁcantly
increased lipid peroxidation and DNA damage in breast,54,55
brain,56 colorectal,57 lung,58 liver,59 head and neck60 cancers, and
oral squamous cell61 carcinoma.
The oxidation of lipid or lipid peroxidation is one of the most
commonly reported indices of OS which is recognized as a path-
ological factor contributing to chronic disease including cancer
and aging.62,63 The most frequently studied markers of lipid per-
oxidation are MDA and isoprostanes.64 Of 23 studies, 14 studies
measured OS with MDA and reported OS to be associated with
PCa. In those studies, high levels of OS in PCa were consistent,
although, MDA was measured using different methods such as
Fig. 2. Forest plot for malondialdehyde. For each study, the marker indicates the effect size and the error bars are 95% conﬁdence intervals. For Arsova-Saraﬁnovska et al, “M”
indicates Macedonian patients and “T” indicates Turkish patients.
Fig. 3. Forest plot for superoxide dismutase. For each study, the marker indicates the effect size and the error bars are 95% conﬁdence intervals. For Arsova-Saraﬁnovska et al, “M”
indicates Macedonian patients and “T” indicates Turkish patients.
Fig. 4. Forest plot for glutathione peroxidase. For each study, the marker indicates the effect size and the error bars are 95% conﬁdence intervals. For Arsova-Saraﬁnovska et al, “M”
indicates Macedonian patients and “T” indicates Turkish patients.
Prostate Int 4 (2016) 71e8784thiobarbituric acid test, thiobarbituric acid-reactive substances
test, and chromatographic assays (high performance liquid
chromatography-diode array detection-ﬂuoro and Liquid chro-
matographyemass spectrometry- diode array detection). One
study reported that MDA levels correlated with the Gleason score
and progression of disease.36 However, another study43 observed
an association between OS and advanced PCa but not localized
PCa. To conﬁrm this result will require further studies with an
adequate sample size.
Four studies measured lipid peroxidation with isoprostanes,
which are prostaglandin-like compounds formed from the free
radical catalyzed peroxidation of arachidonic acid. Two studies48,50
reported urine F2-isoprostane generated by lipid peroxidation to beassociated with PCawhilst two other studies did not.31,53 These two
studies31,53 were likely hampered by the limitation of small sample
sizes. Further, differences in study populations may also be a cause
of divergent ﬁndings. One study53 was conducted in diabetic and
hypoglycemia patients while the former two studies were con-
ducted in nondiabetic patients.
To measure outcomes of protein oxidation, DNA damage with 8-
OHdG and with NO2e or NO3e are commonly used in cancer
research.64 Three studies reported a difference of 8-OHdG between
two groups while one study did not observe a difference. The latter
study suggested that there was a need to improve the validated
analytical procedure of measuring 8-OHdG using plasma or serum
samples. The results of these three studies are similar to previous
Oh et al / Review of case control studies 85studies which demonstrated that higher DNA damage correlated
with the risk of PCa.65,66
Three studies which measured protein oxidation with NO2e or
NO3e showed OS to be consistently higher in PCa. These ﬁndings
are in agreement with previous studies which suggested that ROS,
including oxygen and nitrogen-free radicals, may cause speciﬁc
oxidative DNA damage and play a leading role in initiation and
promotion of carcinogenesis.67
CAT, SOD, and GSH related enzymes are considered primary
endogenous antioxidants while vitamins C, E, and A (converted
from beta-carotene) are considered exogenous antioxidants as
they are directly involved in elimination of ROS.46,68 Both
endogenous and exogenous antioxidants protect cells against
ROS induced during metabolism in living organisms.46 For
example, GSH-Px removes both H2O2 and lipid peroxides using
GSH. SOD metabolizes and protects the cells against O2e, medi-
ated by lipid peroxidation, and CAT acts on H2O2 and decomposes
it to H2O and OHe. The exogenous antioxidants (vitamins A, C,
and E) at the molecular and cellular level are also considered to
be effective in eliminating free radicals and prevent chronic
diseases including cancer.68 Thus, our review further evaluated
the relationship between antioxidants and men with PCa, in
addition to OS.
Fifteen studies measured antioxidant indicators. SOD was
measured in eight studies with erythrocytes or whole blood. Five
studies reported low SOD levels in patients while two studies42,47
reported contrasting results, and one study49 found no differ-
ences. CAT was measured on erythrocytes and whole blood sam-
ples in six studies. Four studies44e47 reported lower CAT levels in
patients and two studies40,49 found no differences. Themain reason
for the inconsistency in SOD and CAT values could be attributed to
the progression of disease.49 This hypothesis is consistent with
Battisit et al47 who observed that an alteration in CAT and SOD
values existed between patients with localized disease and those
with bone metastases.
Further, four studies reported lower GSH levels in patients
whereas two studies reported conﬂicting results.44,47 All seven
studies that measured GSH-Px showed GSH-Px values to be lower
in patients. In contrast, GST values were higher in men with PCa.
Overall, the GSH-dependent enzyme levels were either decreased
or increased or unchanged. The reason for the inconsistency of
GSH-dependent enzyme activities could be inﬂuenced by the
prostate-speciﬁc antigen values, as suggested by several
studies.45,51 Furthermore, GSH and GSH-dependent enzymes have
been known to be of central importance in the detoxiﬁcation of
peroxides, hydroperoxides, xenobiotics, and drugs.69 Hence,
modiﬁcation of GSH-dependent enzyme activities can be explained
by the interdependence and dynamics of the GSH enzyme family
pathway. GSH is turned to gluthathione disulﬁde by GSH-Px. Glu-
thathione disulﬁde is reduced again by GR using nicotinamide
adenine dinucleotide phosphate as a cofactor. GSH has the ability to
directly scavenge cellular ROS nonenzymatically as well as serving
as a cofactor for GSH-Px in the reduction of H2O2 and other
peroxide species.70 GSH-Px is also responsible for detoxifying other
lipid peroxides to the corresponding alcohol.70 GST catalyzes the
conjugation of GSH to a wide variety of endogenous and exogenous
electrophilic compounds. GSH conjugation is the ﬁrst step in the
mercapturic acids pathway that leads to the elimination of toxic
compounds.71
Six studies measured exogenous antioxidant sub-
stances.35,39,41,43,45,47,51 Both vitamin A (including beta-carotene,
lycopen, leutin) and vitamin C were found to be lower in patients
with PCa. With regard to vitamin E, four studies found lower levels
in patients whereas one study43 reported contrasting results. The
authors43 attributed this difference to different study populations.Patients participating in this study received ADT whilst most other
studies included patients who did not receive anticancer treatment.
ADT may alter vitamin E levels. Future studies are needed to
conﬁrm this.
A major limitation of this review is the inability to control for
potential confounding factors. It is possible that the risk of PCa is
inﬂuenced by multiple factors such as radiation, pollution, alcohol,
diet, smoking, anxiety and stress, inﬂammation, drugs, and chronic
diseases, which can all modulate OS levels. Most papers included in
this review did not report these variables. Despite this limitation,
our results suggest that redox imbalance is more common in men
with PCa which may be useful for designing future randomized
controlled trials.
In conclusion, the results of our review suggest that dysre-
gulation of redox balance occurs in patients with PCa. OS bio-
markers MDA and 8OH-dg as well as antioxidant parameters
SOD, CAT, GSH enzyme family, and vitamins C and E may be
potentially predictive biomarkers of PCa. Robust studies are
required to elucidate whether reduced antioxidant enzyme levels
are caused by the counteraction to OS or enhanced oxidation,
which occurs as a result of depleted antioxidants over a pro-
longed period of time.
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